Pieter A van Doorn Selected Research

Glycogen Storage Disease Type II (Pompe's Disease)

12/2022	MRI changes in diaphragmatic motion and curvature in Pompe disease over time.
1/2022	Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
1/2022	Is the brain involved in patients with late-onset Pompe disease?
11/2019	Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
1/2018	The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
12/2017	Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
1/2017	Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.
3/2016	Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.
2/2016	Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease.
10/2015	Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pieter A van Doorn Research Topics

Disease

44	Guillain-Barre Syndrome 01/2022 - 04/2003
26	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2022 - 06/2005
25	Glycogen Storage Disease Type II (Pompe's Disease) 12/2022 - 06/2003
12	Polyneuropathies (Polyneuropathy) 01/2022 - 12/2005
7	Pain (Aches) 11/2021 - 10/2007
7	Disease Progression 02/2017 - 03/2002
7	Infections 08/2014 - 04/2005
5	Autoimmune Diseases (Autoimmune Disease) 12/2015 - 06/2010
4	Muscle Weakness 01/2021 - 03/2002
4	Respiratory Insufficiency (Respiratory Failure) 02/2017 - 06/2010
4	Inflammation (Inflammations) 02/2017 - 02/2010
4	Hypertension (High Blood Pressure) 01/2017 - 02/2010
4	Muscular Diseases (Myopathy) 10/2015 - 06/2003
3	Neuralgia (Stump Neuralgia) 11/2021 - 01/2018
3	Sudden Infant Death (SID) 01/2021 - 06/2013
3	Fatigue 12/2014 - 03/2011
3	Miller Fisher Syndrome (Fisher Syndrome) 06/2013 - 10/2008
3	Diarrhea 03/2011 - 02/2008
2	COVID-19 06/2022 - 05/2022
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 03/2014
2	Diabetes Mellitus 01/2016 - 06/2007
2	Neuromuscular Diseases (Neuromuscular Disease) 12/2015 - 06/2010
2	Monoclonal Gammopathy of Undetermined Significance 12/2015 - 09/2015
1	AIDS-Related Complex (ARC) 06/2022
1	Breakthrough Infections 06/2022
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Epstein-Barr Virus Infections 01/2021
1	Multiple Sclerosis 01/2021
1	Multiple Myeloma 01/2018
1	Painful Neuropathy 01/2018
1	Hyperalgesia 12/2017
1	Hypoalbuminemia 02/2017
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2017
1	Sepsis (Septicemia) 01/2017
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2016

Drug/Important Bio-Agent (IBA)

35	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 06/2005
14	AntibodiesIBA 06/2022 - 04/2003
11	Immunoglobulin G (IgG)IBA 01/2022 - 05/2005
11	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 05/2009
11	GangliosidesIBA 01/2016 - 04/2003
7	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 11/2010
6	Immunosuppressive Agents (Immunosuppressants)IBA 06/2022 - 11/2010
6	AcidsIBA 11/2013 - 08/2005
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2011
5	Methotrexate (Mexate)FDA LinkGeneric 01/2017 - 03/2002
4	alpha-Glucosidases (Acid Maltase)IBA 01/2022 - 06/2003
4	human GAA protein (Myozyme)FDA Link 01/2022 - 12/2010
4	Amantadine (Aman)FDA LinkGeneric 01/2021 - 03/2011
4	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2017 - 05/2009
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 05/2009
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017 - 05/2009
4	Rituximab (Mabthera)FDA Link 01/2017 - 05/2009
4	Azathioprine (Imuran)FDA LinkGeneric 01/2017 - 05/2009
4	GlycogenIBA 10/2015 - 08/2007
4	GlucosidasesIBA 11/2013 - 12/2010
3	AntigensIBA 06/2022 - 04/2003
3	Immunomodulating AgentsIBA 01/2017 - 11/2010
3	InterferonsIBA 01/2017 - 05/2009
3	Glucose (Dextrose)FDA LinkGeneric 12/2016 - 06/2007
3	Insulin (Novolin)FDA Link 10/2016 - 02/2010
3	Immunoglobulin M (IgM)IBA 12/2015 - 12/2005
3	CaprylatesIBA 02/2012 - 02/2008
2	EnzymesIBA 01/2022 - 08/2007
2	Methylprednisolone FDA LinkGeneric 01/2022 - 10/2007
2	Pharmaceutical PreparationsIBA 11/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2009
2	Biological ProductsIBA 01/2017 - 08/2016
2	Interferon beta-1a FDA Link 01/2017 - 06/2013
2	Creatine Kinase (Creatine Phosphokinase)IBA 02/2016 - 03/2002
2	Interferon-betaIBA 06/2013 - 11/2010
2	Interferon-alpha (Interferon Alfa)IBA 06/2013 - 11/2010
2	Indicators and Reagents (Reagents)IBA 03/2011 - 06/2010
2	IceIBA 09/2010 - 02/2008
2	OligosaccharidesIBA 07/2010 - 02/2008
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Natalizumab (Tysabri)FDA Link 01/2021
1	N 30IBA 01/2020
1	Alemtuzumab (Campath)FDA Link 01/2020
1	SaltsIBA 12/2019
1	PanzygaIBA 01/2018
1	Bortezomib (Velcade)FDA Link 01/2018
1	Purinergic P2X3 ReceptorsIBA 12/2017
1	Serum AlbuminIBA 02/2017
1	AlbuminsIBA 02/2017
1	LipidsIBA 01/2017

Therapy/Procedure

18	Enzyme Replacement Therapy 12/2022 - 06/2003
10	Plasma Exchange 11/2021 - 06/2005
9	Therapeutics 01/2022 - 06/2005
5	Artificial Respiration (Mechanical Ventilation) 02/2017 - 06/2010
3	Immunotherapy 01/2021 - 02/2004
3	Aftercare (After-Treatment) 02/2017 - 03/2014
3	Mechanical Ventilators (Ventilator) 05/2015 - 08/2011
2	Enzyme Therapy 11/2019 - 09/2012
2	Activities of Daily Living (ADL) 07/2017 - 03/2015
1	Drug Tapering 01/2018
1	Ligation 12/2017
1	Tracheostomy 01/2017
1	Central Venous Catheters 01/2017
1	Catheters 01/2017